RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > European Commission: Cranberry Products Are Not Medical Devices

European Commission: Cranberry Products Are Not Medical Devices

Posted 26 May 2017 | By Zachary Brennan 

European Commission: Cranberry Products Are Not Medical Devices

The European Commission's regulatory committee on medical devices on 19 May voted in favor of the commission's decision that products "whose principal intended action, depending on proanthocyanidins (PAC) present in cranberry extract, is to prevent or treat cystitis," also known as bladder inflammation or infection, "are not medical devices within the meaning of Article 1 (2) (a) of the Medical Devices Directive."

The final decision, following a draft decision in February 2016, comes as last July, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) noted: "Products containing proanthocyanidins and/or cranberry as substance or preparation for use in urinary tract infections [UTIs] are currently marketed differently across the EU as food supplement, medical device or consumer product."

While considering the information provided by the commission, the definition of a medical device, an EC guidance document, a ruling in the Court of Justice of the European Union from 2012 and the scientific literature, CHMP said in its opinion, "The totality of data suggests that a mechanical mode of action of PACs is highly unlikely. Metabolites of PACs and other constituents of cranberry exhibit most probably a pharmacological activity."

In 2014, the French company Arkopharma had its EU medical device status revoked by France's medical products regulator (ANSM) after obtaining Class IIb medical device status for its patented cranberry-based products based on clinical data. ANSM said at the time that Arkopharma lacked the data to justify its device status.

The formal adoption and publication of the commission's decision are expected later this summer.

Adoption of the Commission decision on the qualification of cranberry products


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.